About Zymenex
Zymenex is a Healthcare company based in Hillerød (Denmark) founded in 1998, and was acquired by Chiesi Pharmaceuticals in August 2013. Enzyme replacement therapies for the treatment of lysosomal storage diseases such as Alpha-Mannosidosis, Krabbe disease. Zymenex has completed 1 acquisition, including Ace BioSciences. Its chief executive, as recorded, is Jens Fogh. The company was acqui-hired. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its legal entity is ZYMENEX ApS.
Company details
Zymenex is focused on the development and commercialization of novel enzyme replacement therapies for the treatment of rare genetic diseases (Lysosomal Storage Diseases). It is developing several human recombinant enzymes that can be used for therapy within specific disease areas. Zymenex pipeline includes Lamazym (a Phase III recombinant enzyme) for the treatment of the Alpha-Mannosidosis; and other preclinical enzyme therapies for Globoid Cell Leukodystrophy (Krabbe disease) and Aspartylglucosaminuria. As of August 2013, Zymenex operates as a subsidiary of Chiesi Group.
- Headquarters Hillerød, Denmark
- Stage Acquired
- SectorsHealthcare
- Website zymenex.com
- Social LinkedIn
- Acquired by Chiesi Pharmaceuticals (Aug 2013)
- Legal Name Zymenex Aps
- Investors
- Investments & Acquisitions
- Acquired byChiesi Pharmaceuticals
(Aug 2013)
Investors in Zymenex
Zymenex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Chiesi Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of drugs for respiratory, neonatology, rare disease and special care therapeutic areas | 1935 | chiesi.com | Parma, Italy |
Investor details for Zymenex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zymenex
1 people are tracked at Zymenex (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jens Fogh | CEO | Leadership |
Complete people profiles for Zymenex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zymenex
Zymenex has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ace BioSciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vaccines for bacterial infection prevention and treatment are provided. | acebiosciences.com | Odense, Denmark | 2000 | Nov 2009 | •••• |
Complete acquisition details for Zymenex
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Zymenex
3 dated milestones of Zymenex across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Zymenex is founded.
- Acquisition Acquires Ace BioSciences.
- Exit Acquired by Chiesi Pharmaceuticals.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zymenex
Complete news archive for Zymenex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zymenex
Zymenex was founded in 1998.
Zymenex is headquartered in Hillerød, Denmark.
Jens Fogh is the CEO of Zymenex, as recorded in our data.
Zymenex is focused on the development and commercialization of novel enzyme replacement therapies for the treatment of rare genetic diseases (Lysosomal Storage Diseases). It is developing several human recombinant enzymes that can be used for therapy within specific disease areas. Zymenex pipeline includes Lamazym (a Phase III recombinant enzyme) for the treatment of the Alpha-Mannosidosis; and other preclinical enzyme therapies for Globoid Cell Leukodystrophy (Krabbe disease) and Aspartylglucosaminuria. As of August 2013, Zymenex operates as a subsidiary of Chiesi Group.
Zymenex has made 1 acquisition, including Ace BioSciences.
Zymenex has 1 investor. Key investors include Chiesi Pharmaceuticals.
Zymenex operates through Zymenex Aps.
Yes. Zymenex was acquired by Chiesi Pharmaceuticals in August 2013.